Scrima Giulia Domna, Sarti Cristina, Pracucci Giovanni, Nistri Rita, Rapillo Costanza Maria, Piccardi Benedetta, Stolcova Miroslava, Ristalli Francesca, Mattesini Alessio, Nozzoli Carlo, Morettini Alessandro, Moggi Pignone Alberto, Nencini Patrizia, Di Mario Carlo, Marcucci Rossella, Meucci Francesco
Department of Neurofarba, University of Florence, 50134 Florence, Italy.
Stroke Unit, Careggi University Hospital (AOUC), 50139 Florence, Italy.
J Clin Med. 2025 Aug 25;14(17):6012. doi: 10.3390/jcm14176012.
: Atrial fibrillation (AF) is associated with high risk of ischaemic stroke (IS). Oral anticoagulant therapy (OAT) is the standard of care for stroke prevention, even though its management remains challenging in clinical practice. An emerging problem is embolic events occurring on adequately conducted OAT, the so-called resistant stroke (RS). We aimed to describe pre-stroke prevention therapy, management on hospital discharge, and therapy at follow-up in all patients with AF hospitalized for IS and in the RS subgroup. : We conducted a retrospective monocentric study of patients with known AF hospitalized for an IS. A subgroup with RS was identified. We recorded information on prevention therapy at home, recommended therapy at discharge, and data on outcome and prevention therapy at follow-up. : We identified 226 patients, 61% females, median age 84.04 years. Preventive therapy at home was performed in 121 (53.5%) (119 OAT and 2 Left Atrial Appendage Occlusion). At hospital discharge OAT was prescribed to 78.2% of patients. RS was diagnosed in 33 patients whose management at discharge was: same OAT in 12, shift to another Direct Oral Anticoauglant (DOAC) in 5, from DOAC to Vitamin K Antagonist (VKA) and vice versa in 11, non-specified OAT in 4. At final, follow-up of 208 days (range 85-443) 23.3% (34/146) did not assume OAT. OAT was significantly associated with survival probability ( < 0.001). : Our findings confirm a scarce adoption of guidelines for AF-related embolic events, even in the absence of absolute contraindication to OAT. RS remains an underexplored clinical entity with empirical management, highlighting the need for targeted research and tailored therapeutic strategies.
心房颤动(AF)与缺血性卒中(IS)的高风险相关。口服抗凝治疗(OAT)是预防卒中的标准治疗方法,尽管其在临床实践中的管理仍然具有挑战性。一个新出现的问题是在充分进行OAT治疗时发生的栓塞事件,即所谓的难治性卒中(RS)。我们旨在描述所有因IS住院的AF患者以及RS亚组患者的卒中前预防治疗、出院时的管理和随访时的治疗情况。
我们对因IS住院的已知AF患者进行了一项回顾性单中心研究。确定了一个RS亚组。我们记录了在家中的预防治疗信息、出院时推荐的治疗方法以及随访时的结局和预防治疗数据。
我们确定了226例患者,其中61%为女性,中位年龄84.04岁。121例(53.5%)患者在家中进行预防性治疗(119例接受OAT,2例接受左心耳封堵)。出院时78.2%的患者被开具OAT。33例患者被诊断为RS,其出院时的管理情况为:12例继续相同的OAT治疗,5例改用另一种直接口服抗凝剂(DOAC),11例从DOAC转换为维生素K拮抗剂(VKA)或反之,4例未明确指定OAT。最终,在208天(范围85 - 443天)的随访中,23.3%(34/146)的患者未接受OAT。OAT与生存概率显著相关(<0.001)。
我们的研究结果证实,即使在没有OAT绝对禁忌证的情况下,AF相关栓塞事件的指南应用也很少。RS仍然是一个研究不足的临床实体,治疗多为经验性,这凸显了针对性研究和个性化治疗策略的必要性。